Voeller Julie, Sondel Paul M
Department of Pediatrics, Division of Hematology, Oncology and Bone Marrow Transplant.
Departments of Human Oncology and Genetics and Carbone Cancer Center, University of Wisconsin, Madison, WI.
J Pediatr Hematol Oncol. 2019 Apr;41(3):163-169. doi: 10.1097/MPH.0000000000001369.
Neuroblastoma (NBL) is the most common extracranial solid tumor in pediatrics, yet overall survival is poor for high-risk cases. Immunotherapy regimens using a tumor-selective antidisialoganglioside (anti-GD2) monoclonal antibody (mAb) have been studied for several decades now, but have only recently been incorporated into standard of care treatment for patients with high-risk NBL with clear benefit. Here we review a brief history of anti-GD2-based immunotherapy, current areas of neuroblastoma research targeting GD2, and potential diagnostic and therapeutic uses targeting GD2.
神经母细胞瘤（NBL）是儿科最常见的颅外实体瘤，但高危病例的总体生存率较低。使用肿瘤选择性抗二唾液酸神经节苷脂（抗GD2）单克隆抗体（mAb）的免疫治疗方案已经研究了几十年，但直到最近才被纳入高危NBL患者的标准治疗中，并取得了明显的益处。在此，我们回顾基于抗GD2免疫治疗的简史、目前针对GD2的神经母细胞瘤研究领域，以及针对GD2的潜在诊断和治疗用途。
